Recommendations include screening for and addressing adverse social determinants of health
What Is Impella- Bobbi Bogaev Chapman
0 seconds of 1 minute, 20 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Shortcuts Open/Close/ or ?
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
Empagliflozin offers cardiorenal benefits for up to 12 months after discontinuation among CKD patients at risk for progression
2010 to 2023 Saw Increase in GLP-1 RA, SGLT2 Inhibitor Use in Type 1 Diabetes
Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity